Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David, Ranjana H. Advani, Timothy S. Fenske, Stefan K. Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S. Kahl, Stephen M. Ansell
Topics & Concepts
Brentuximab vedotinNivolumabMedicineIpilimumabOncologyRefractory (planetary science)Internal medicineOpen labelHodgkin lymphomaPhases of clinical researchLymphomaClinical trialImmunotherapyCancerMaterials scienceComposite materialLymphoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCAR-T cell therapy research